Blue Cross NC policies, page 2

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

Checking prior authorization for 81479? Open Blue Cross NC’s official lists and confirm the member’s product there.

101 policies name 81479, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Blue Cross NC policies
PolicyDetailsCodesSource
Genetic Testing for Acute Myeloid Leukemia AHS-M2062AHS-M2062 · Commercial15Original policy ↗
Genetic Testing for Muscular Dystrophies AHS – M2074M2074 · Commercial15Original policy ↗
Molecular Markers in Fine Needle Aspirates of the ThyroidM2108 · Commercial15Original policy ↗
Genetic Testing for Inherited Cardiomyopathies and Channelopathies AHS – M2025M2025 · Commercial17Original policy ↗
Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease AHS – G2121G2121 · Effective Oct 1, 2025 · Commercial18Original policy ↗
Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers (BRCA) AHS - M2003M2003 · Commercial19Original policy ↗
Genetic Testing for Neurofibromatosis and Related Disorders AHS – M2134M2134 · Commercial19Original policy ↗
Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers (BRCA) AHS - M2003M2003 · Commercial20Original policy ↗
Proteogenomic Testing of Individuals with Cancer AHS - M2168M2168 · Commercial20Original policy ↗
Minimal Residual Disease (MRD) AHS - M2175M2175 · Commercial21Original policy ↗
Transplant Rejection Testing AHS - M2091M2091 · Commercial21Original policy ↗
Genetic Testing of Mitochondrial Disorders AHS – M2085M2085 · Commercial22Original policy ↗
Molecular Diagnostics for Breast Cancer Prognosis AHS - M2020M2020 · Commercial22Original policy ↗
Pharmacogenetics Testing AHS – M2021M2021 · Commercial22Original policy ↗
Prenatal Screening for Fetal Aneuploidy AHS –G2055G2055 · Commercial24Original policy ↗
Transplant Rejection Testing AHS - M2091 NotificationM2091 · Commercial24Original policy ↗
Whole Genome and Whole Exome Sequencing AHS – M2032M2032 · Commercial26Original policy ↗
Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030 "Notification"M2030 · Commercial27Original policy ↗
Lynch Syndrome AHS - M2004M2004 · Commercial28Original policy ↗
Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030M2030 · Commercial28Original policy ↗
Genomic Testing for Hematopoietic Neoplasms AHS- M2182AHS-M2182 · Commercial29Original policy ↗
Genome and Exome Sequencing AHS – M2032M2032 · Commercial30Original policy ↗
Genome and Exome Sequencing AHS – M2032 NotificationM2032 · Commercial30Original policy ↗
Prenatal Testing for Fetal Aneuploidy AHS - G2055G2055 · Commercial30Original policy ↗
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer AHS - M2166AHS - M2166 · Commercial31Original policy ↗
Esophageal Pathology Testing AHS – M2171M2171 · Commercial32Original policy ↗
Esophageal Pathology Testing AHS - M2171M2171 · Commercial34Original policy ↗
Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101M2101 · Commercial35Original policy ↗
Red Blood Cell Molecular Testing AHS - M2170AHS-M2170 · Commercial52Original policy ↗
Microsatellite Instability and Tumor Mutational Burden Testing AHS - M2178AHS-M2178 · Commercial53Original policy ↗
General Genetic Testing, Somatic Disorders AHS-M2146AHS-M2146 · Commercial54Original policy ↗
Prenatal Screening (Genetic) AHS – M2179M2179 · Commercial54Original policy ↗
Testing for Diagnosis of Active or Latent Tuberculosis AHS - G2063G2063 · Commercial55Original policy ↗
Genetic Testing for Neurodegenerative Disorders AHS – M2167M2167 · Commercial60Original policy ↗
Molecular Testing for Cutaneous Melanoma AHS - M2029M2029 · Commercial60Original policy ↗
Genomic Testing for Hematopoietic Neoplasms AHS- M2182AHS- M2182 · Commercial62Original policy ↗
Genetic Testing for Cystic Fibrosis AHS – M2017M2017 · Commercial64Original policy ↗
Prenatal Screening (Genetic) AHS - M2179M2179 · Commercial67Original policy ↗
Prenatal Screening (Genetic) AHS - M2179 NotificationM2179 · Commercial67Original policy ↗
General Genetic Testing, Germline Disorders AHS – M2145M2145 · Commercial77Original policy ↗
Serum Tumor Markers for Malignancies AHS - G2124G2124 · Commercial78Original policy ↗
Pre-Implantation Genetic Testing AHS - M2039M2039 · Commercial83Original policy ↗
Laboratory Procedures Medical Policy AHS - R2162 NotificationAHS - R2162 · Commercial84Original policy ↗
Pharmacogenetics Testing AHS - M2021M2021 · Commercial89Original policy ↗
General Genetic Testing, Somatic Disorders AHS - M2146AHS-M2146 · Commercial92Original policy ↗
Liquid Biopsy AHS - G2054 NotificationG2054 · Commercial92Original policy ↗
Laboratory Procedures Medical Policy AHS - R2162AHS - R2162 · Commercial93Original policy ↗
Laboratory Procedures Medical Policy AHS - R2162 NotificationAHS - R2162 · Commercial95Original policy ↗
Liquid Biopsy AHS - G2054G2054 · Commercial95Original policy ↗
Prenatal Screening AHS – G2035G2035 · Commercial106Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.